SQ-LIP-000004 · v1.4 (archived) · View current version →

Is lipedema underdiagnosed, and can screening tools help identify it?

Knowledge freshness = share of the 36 indexed evidence sources from the last 5 years (newest 2026, oldest 2008) . Low freshness flags an ageing evidence base — not that the answer is wrong.

Evidence over time

supporting   contradicting   refining / context Each dot is a study, placed by year and coloured by whether the linked claim supports or contradicts the answer. As the surveillance loop runs, claim revisions and new evidence will extend this timeline.

Supporting claims

• SCR-LIP-000007 supporting
  Because obesity is commonly defined by BMI alone (which disregards fat distribution), lipedema is frequently underdiagnosed when workup stops at an established obesity diagnosis; ~81% of lipedema patients are classified overweight/obese by BMI.
  Ultrasound criteria for lipedema diagnosis — Amato et al. (2021) · Amato ACM, 2021
• SCR-LIP-000008 supporting
  A self-administered lipedema screening questionnaire achieves a high probability of correct classification (~91%) between women with and without lipedema, supporting its use to raise clinical suspicion.
  Criação de questionário e modelo de rastreamento de lipedema — Amato et al. (2020)
• SCR-LIP-000009 supporting
  The Brazilian Portuguese lipedema symptoms questionnaire (QuASiL) was translated, culturally adapted and validated, showing high comprehension and symptom-intensity scores that correlate with limb volume by segmental bioimpedance.
  Tradução, adaptação cultural e validação do questionário de avaliação sintomática do lipedema (QuASiL) — Amato et al. (2020)
• SCR-LIP-000062 supporting
  A narrative review of 2020–2025 evidence concludes that systematic lipedema screening is necessary when studying pain–inflammation relationships in women with obesity, because unrecognized lipedema may cluster pain within peripheral fat phenotypes and bias comparisons between android and gynoid obesity groups.
  Dor crônica e biomarcadores inflamatórios em mulheres com obesidade: Impacto dos Fenótipos Adiposos e Lipedema — Silva et al. (2026)
• SCR-LIP-000064 supporting
  In a cross-sectional study of 115 female patients in Saudi Arabia, only 71% received a clinical diagnosis of lipedema despite presenting to a specialized clinic, and the study authors characterize this as a high underdiagnosis rate requiring increased awareness.
  Characteristics and Clinical Features of Patients with Lipedema in Saudi Arabia: A Cross-sectional Comprehensive Assessment — Alosaimi et al. (2024) · Lipedema awareness and knowledge level among medical doctors in Turkey: A cross-sectional study highlighting the diagnosis and treatment gap — Bagatir et al. (2025)
• SCR-LIP-000065 supporting
  In a cohort of 1803 Spanish lipedema patients, 60.6% were diagnosed during reproductive years with a mean age of 42.9 years, and the study presents a novel clinical assessment approach including multiple comorbidity markers (e.g., suspected high intestinal permeability in 99%, bilateral trochanteric pain in 97.4%, ligamentous hyperlaxity in 95.8%) that may help physicians better identify and understand the condition.
  Clinical Signs at Diagnosis and Comorbidities in a Large Cohort of Patients with Lipedema in Spain — Simarro Blasco et al. (2025)
• SCR-LIP-000066 supporting
  A cross-sectional study of 1069 Spanish patients found a real diagnostic problem with lipedema and proposed that patients presenting six or more of a defined set of diagnostic criteria have a very high probability of having lipedema, supporting active screening with symptom-based criteria.
  The Advanced Care Study: Current Status of Lipedema in Spain, A Descriptive Cross-Sectional Study — Carballeira Braña & Poveda Castillo (2023)
• SCR-LIP-000068 supporting
  Dutch lipedema guidelines conclude that lipedema is frequently misdiagnosed or wrongly classified as an aesthetic problem, and recommend a minimum data set of repeated clinical measurements (waist circumference, limb circumferences, BMI, and psychosocial distress scoring) to ensure early detection.
  First Dutch guidelines on lipedema using the international classification of functioning, disability and health — Halk & Damstra (2017)
• SCR-LIP-000069 supporting
  Lipedema is often unrecognized or misdiagnosed despite an estimated prevalence of 10% in the overall female population, and diagnosis currently relies on clinical grounds alone due to the lack of specific biomarkers or objective measuring instruments.
  Lipedema—Pathogenesis, Diagnosis, and Treatment Options — Kruppa et al. (2020) · Lipedema: Clinical Features, Diagnosis, and Management — Mortada et al. (2025) · Lipoedema is not lymphoedema: A review of current literature — Shavit et al. (2018) · Lipedema: What we don’t know — van la Parra et al. (2023)
• SCR-LIP-000070 supporting
  A systematic review of 61 studies found that lipedema is chronically underdiagnosed and misdiagnosed as obesity or lymphedema, delaying care, and identified a need for standardized diagnostic criteria and validated patient-reported outcomes to improve recognition.
  Lipedema Diagnosis, Clinical Manifestations, and Therapeutics: A Systematic Review — Vazirnia et al. (2026)
• SCR-LIP-000275 supporting
  Using a previously validated online screening questionnaire (cutoff ≥12 points, AUC 0.8615, specificity 0.88, sensitivity 0.46, PPV 0.767), a population-representative study estimated lipedema prevalence at 12.3% among Brazilian women aged 18-69, corresponding to roughly 8.8 million women with suggestive symptoms.
  DOI:10.1590/1677-5449.202101981
• SCR-LIP-000276 supporting
  In a surgical lipedema cohort, abdominal involvement was found in 31% of stage II and 70% of stage III patients and was described as under-recognized; the authors propose a clinical-ultrasonographic diagnostic algorithm (maximal, major, and minor criteria, including hyperechoic subcutaneous nodules) to improve identification of abdominal lipedema.
  DOI:10.1007/s00266-025-05192-1
• SCR-LIP-000277 supporting
  In non-obese lipedema patients, standardized QST (DFNS protocol) revealed selective alterations in only 2 of 13 parameters at the affected lateral thigh—elevated pressure pain (PPT, AUC 0.9075) and reduced vibration detection (VDT, AUC 0.8638)—and a combined PPT+VDT z-score score was proposed as a rapid diagnostic test for lipedema.
  DOI:10.1101/2023.04.25.23289086
• SCR-LIP-000278 supporting
  In a DXA body composition study, the leg fat mass/total fat mass index distinguished lipedema patients from controls across all BMI strata with AUC=0.90 (sensitivity 0.95, specificity 0.73 at cutoff 0.383), and was proposed as a simple screening tool to help exclude lipedema in doubtful cases alongside clinical criteria, which the authors note are subjective and unreliable.
  DOI:10.1159/000527138
• SCR-LIP-000280 supporting
  This reply letter states that lipedema is frequently underdiagnosed and confused with obesity and lymphedema (worsened by phonetic similarity among 'lipedema', 'lipidemia', and 'lipemia'), and defends an ultrasound diagnostic cutoff incorporating dermal and subcutaneous thickness (mean subcutaneous thigh thickness 20.9 mm in lipedema vs 12.67 mm in controls).
  DOI:10.1177/02683555211068953
• SCR-LIP-000284 supporting
  This narrative review describes lipedema as a common but rarely diagnosed condition frequently confused with obesity, emphasizing that early recognition based on the diagnostic triad of spontaneous pain, pressure pain, and easy bruising is essential to prevent progression.
  DOI:10.1556/oh.2008.28490
• SCR-LIP-000285 supporting
  A systematic review reported that lipedema is poorly recognized clinically—only 46.2% of 251 Vascular Society of Great Britain and Ireland consultants recognized it (Tiwari 2006)—and that it was absent from MeSH/EMBASE and ICD-WHO as of 2012, while non-contrast CT showed 95% sensitivity and 100% specificity and the spared foot dorsum (negative Stemmer sign) helps distinguish lipedema from lymphedema.
  DOI:10.1111/j.1758-8111.2012.00045.x
• SCR-LIP-000286 supporting
  Bioimpedance spectroscopy measuring a leg/arm ratio of extracellular water (R0) distinguished stage 1 lipedema from BMI-matched controls (p=0.01 for R0 ratio, p=0.007 for R1 ratio) and differentiated lipedema from Dercum's disease (lower leg/arm ratio in lipedema, p<0.001), indicating non-invasive detection of early-stage disease.
  DOI:10.1089/lrb.2019.0011
• SCR-LIP-000287 supporting
  In a case-control study, carriers of the IL-6 rs1800795 G allele had a 5.92-fold higher risk of lipedema (OR=5.92, 95%CI 1.983–17.711, p<0.001), and DXA-derived body composition indices (reduced WHR 0.73 vs 0.79, higher lower-limb FM% 48.90% vs 42.55%) combined with genetic analysis were proposed as tools for differential diagnosis between lipedema, normal-weight obesity, and obesity.
  DOI:10.26355/eurrev_202003_20690
• SCR-LIP-000288 supporting
  In a prospective cohort of 138 lipedema and 111 lymphedema patients, a CART algorithm using only three clinical variables (bruising, body disproportion, and non-swollen/spared feet) classified lipedema versus lymphedema with 100% accuracy, and the median time from symptom onset to diagnosis was markedly longer in lipedema (25.5 years vs 12.1 years for lymphedema, p<0.0001).
  DOI:10.23736/s0392-9590.25.05207-1
• SCR-LIP-000289 supporting
  In 50 lipedema patients versus 50 controls, ICG lymphography showed slower superficial lymph flow (ICG reached upper calf in 8% vs 56%, p<0.0001), more visualized lymphatic vessels, higher fluorescence intensity at all limb levels, increased skin water concentration in the feet (p=0.000189), and stiffer subcutaneous tissue, demonstrating these multimodal measures can help diagnose lipedema though precise diagnostic criteria still require further study.
  DOI:10.1089/lrb.2022.0010

Contradictory claims

• None indexed yet.

Refining / context

• SCR-LIP-000063 context
  In a cohort of 191 female patients with lower limb lipedema, the condition is described as 'often misdiagnosed' and affecting approximately 11% of women, with the study focusing on surgical outcomes of ultrasound-assisted liposuction rather than screening tools.
  Observational Study of Ultrasound-Assisted Liposuction for Lower Limb Lipedema on 191 Female Patients — Hersant et al. (2026) · Lipedema: A Relatively Common Disease with Extremely Common Misconceptions — Buck & Herbst (2016) · Lipedema: A Call to Action! — Buso et al. (2019) · Lipedema: Progress, Challenges, and the Road Ahead — Cifarelli (2025)
• SCR-LIP-000067 refines
  A systematic review of 20 studies identified 13 different imaging and measurement tools used to quantify lipedema characteristics, but found a lack of consistency in protocols, measurement locations, and outcome analysis, with limited clinimetric reporting from small and heterogeneous cohorts, preventing recommendation of any single tool for clinical practice.
  Assessment Tools to Quantify the Physical Aspects of Lipedema: A Systematic Review — Eason et al. (2025) · Diagnostic imaging in lipedema: A systematic review — van la Parra et al. (2024)
• SCR-LIP-000279 context
  This editorial commenting on Crescenzi et al. (2023) emphasizes the lack of reliable lipedema biomarkers and highlights noncontrast 3T MR lymphangiography—which reveals subcutaneous adipose tissue edema and increased lymphatic load—as a promising imaging biomarker that could aid differential diagnosis between lipedema and obesity, while noting small sample sizes limit current evidence.
  DOI:10.1002/jmri.28400
• SCR-LIP-000281 context
  In a cross-sectional online survey, lipedema patients more frequently reported hypermobility (44% in adulthood, ~60% in childhood), joint pain, and multisystem symptoms than lymphedema patients, and the authors note lipedema remains underdiagnosed and should be reconceptualized as a systemic connective tissue disorder.
  DOI:10.3390/jcm14207195
• SCR-LIP-000282 context
  A systematic review of molecular and cellular lipedema research estimated worldwide prevalence at approximately 11% among women, noting this figure is inflated by underdiagnosis and acknowledged diagnostic limitations, but the review focused on molecular biology and did not evaluate screening tools.
  DOI:10.3390/jpm13010098
• SCR-LIP-000283 context
  In a cohort of 83 women with clinically diagnosed lipedema, symptoms began at a mean age of 20.4 years but diagnosis occurred at a mean age of 46.5 years, indicating a mean diagnostic delay of 26.1 years, while lymphoscintigraphy showed lymphatic alterations in 47% of patients across all clinical stages.
  DOI:10.1016/j.remn.2018.06.008

Major uncertainty

The core uncertainty is no longer whether lipedema is underdiagnosed (strongly supported) but whether any screening or diagnostic tool can be reliably recommended for practice. Despite a proliferation of candidate tools—questionnaires, DXA indices, QST scores, bioimpedance, ultrasound, CT/MR imaging, ICG lymphography, and genetic markers—most derive from small, single-center cross-sectional case-control studies with unknown or moderate risk of bias, and high-grade systematic reviews emphasize protocol heterogeneity, limited clinimetric reporting, and absence of prospective comparative validation. Reported diagnostic accuracies (e.g., AUC 0.86–0.90, CT 95%/100%, CART 100%) are promising but unconfirmed in independent populations; the validated questionnaire's low sensitivity (0.46) shows clear miss rates; and there remains no specific biomarker, so diagnosis stays clinical. Whether any single tool or combination will withstand external prospective validation and standardization remains undetermined.

Version history

• SQ-LIP-000004 · v1.4 — 2026-05-31 — This update added numerous candidate diagnostic/screening modalities (QST PPT+VDT score, DXA fat-distribution index, bioimpedance spectroscopy, ultrasound thickness cutoffs, non-contrast CT, ICG and MR lymphangiography, IL-6 genotyping, and a 3-variable CART classifier with 100% accuracy) plus stronger documentation of long diagnostic delays (~25–26 years) and low clinician recognition (46.2% of UK vascular surgeons), reinforcing underdiagnosis while expanding the still-unvalidated toolkit. · view this version
• SQ-LIP-000004 · v1.3 — 2026-05-31 — Answer recompiled after human curation of the claim set. · view this version
• SQ-LIP-000004 · v1.2 — 2026-05-31 — This update substantially expanded the evidence base by adding multiple new supporting studies—including large Spanish cohorts (1069 and 1803 patients), a Saudi Arabian clinic study, a Turkish physician survey, two systematic reviews on imaging and measurement tools, a 61-study systematic review confirming chronic underdiagnosis, Dutch guidelines recommending a minimum measurement data set, and several additional narrative reviews—collectively strengthening the conclusion that lipedema is underdiagnosed across diverse geographic and clinical settings while also refining the assessment of screening tools by documenting their inconsistency and lack of prospective validation. · view this version
• SQ-LIP-000004 · v1.1 — 2026-05-31 — This update added two new pieces of evidence: a 2026 narrative review explicitly calling for systematic lipedema screening to prevent misclassification in pain–inflammation research, and a 2026 surgical cohort that corroborates underdiagnosis by describing lipedema as 'often misdiagnosed' and citing ~11% prevalence, though neither study addresses screening tool validation. · view this version
• SQ-LIP-000004 · v1.0 — 2026-05-30 — founding index (27 claims) · view this version

Key references

DOI:10.1177/02683555211002340 · DOI:10.1590/1677-5449.200114 · DOI:10.1590/1677-5449.200049 · DOI:10.36557/2674-8169.2026v8n2p869-884 · DOI:10.1097/prs.0000000000012217 · DOI:10.1097/gox.0000000000001043 · DOI:10.1002/oby.22597 · DOI:10.1111/obr.13953 · DOI:10.1097/gox.0000000000006173 · DOI:10.1177/02683555251332998 · DOI:10.3390/biomedicines13123049 · DOI:10.3390/ijerph20176647 · DOI:10.1089/lrb.2024.0102 · DOI:10.1111/obr.13648 · DOI:10.1177/0268355516639421 · DOI:10.3238/arztebl.2020.0396 · DOI:10.1055/a-2530-5875 · DOI:10.1111/iwj.12949 · DOI:10.1016/j.bjps.2023.05.056 · DOI:10.1111/ijd.70227 · DOI:10.1590/1677-5449.202101981 · DOI:10.1007/s00266-025-05192-1 · DOI:10.1101/2023.04.25.23289086 · DOI:10.1159/000527138 · DOI:10.1002/jmri.28400 · DOI:10.1177/02683555211068953 · DOI:10.3390/jcm14207195 · DOI:10.3390/jpm13010098 · DOI:10.1016/j.remn.2018.06.008 · DOI:10.1556/oh.2008.28490

← All questions